235 related articles for article (PubMed ID: 15117453)
1. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.
Arya SK
AIDS Res Hum Retroviruses; 1993 Sep; 9(9):839-48. PubMed ID: 8257633
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes.
Zauli G; Gibellini D; Celeghini C; Mischiati C; Bassini A; La Placa M; Capitani S
J Immunol; 1996 Sep; 157(5):2216-24. PubMed ID: 8757349
[TBL] [Abstract][Full Text] [Related]
4. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of the metal binding site in the cysteine-rich region of HIV-1 Tat protein.
Huang HW; Wang KT
Biochem Biophys Res Commun; 1996 Oct; 227(2):615-21. PubMed ID: 8878561
[TBL] [Abstract][Full Text] [Related]
6. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
[TBL] [Abstract][Full Text] [Related]
7. Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.
Devadas K; Boykins RA; Hardegen NJ; Philp D; Kleinman HK; Osa EO; Wang J; Clouse KA; Wahl LM; Hewlett IK; Rappaport J; Yamada KM; Dhawan S
Peptides; 2006 Apr; 27(4):611-21. PubMed ID: 16256245
[TBL] [Abstract][Full Text] [Related]
8. Conservative mutations in the putative metal-binding region of human immunodeficiency virus tat disrupt virus replication.
Sadaie MR; Mukhopadhyaya R; Benaissa ZN; Pavlakis GN; Wong-Staal F
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1257-63. PubMed ID: 2078407
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation.
Valvatne H; Szilvay AM; Helland DE
AIDS Res Hum Retroviruses; 1996 May; 12(7):611-9. PubMed ID: 8743086
[TBL] [Abstract][Full Text] [Related]
10. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
11. Furin cleavage of the HIV-1 Tat protein.
Tikhonov I; Ruckwardt TJ; Berg S; Hatfield GS; David Pauza C
FEBS Lett; 2004 May; 565(1-3):89-92. PubMed ID: 15135058
[TBL] [Abstract][Full Text] [Related]
12. Activity of synthetic tat peptides in human immunodeficiency virus type 1 long terminal repeat-promoted transcription in a cell-free system.
Jeyapaul J; Reddy MR; Khan SA
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7030-4. PubMed ID: 2205850
[TBL] [Abstract][Full Text] [Related]
13. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
14. Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.
Elangovan B; Subramanian T; Chinnadurai G
J Virol; 1992 Apr; 66(4):2031-6. PubMed ID: 1548750
[TBL] [Abstract][Full Text] [Related]
15. The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR.
Chang YN; Jeang KT
Nucleic Acids Res; 1992 Oct; 20(20):5465-72. PubMed ID: 1437564
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis.
Boykins RA; Mahieux R; Shankavaram UT; Gho YS; Lee SF; Hewlett IK; Wahl LM; Kleinman HK; Brady JN; Yamada KM; Dhawan S
J Immunol; 1999 Jul; 163(1):15-20. PubMed ID: 10384093
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F
J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394
[TBL] [Abstract][Full Text] [Related]
19. Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides.
Huq I; Ping YH; Tamilarasu N; Rana TM
Biochemistry; 1999 Apr; 38(16):5172-7. PubMed ID: 10213623
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 subtype C exhibits higher transactivation activity of Tat than subtypes B and E.
Kurosu T; Mukai T; Komoto S; Ibrahim MS; Li YG; Kobayashi T; Tsuji S; Ikuta K
Microbiol Immunol; 2002; 46(11):787-99. PubMed ID: 12516777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
